Single Nucleotide Polymorphism of Interleukin-18 and Interleukin-18 Receptor and the Risk of Papillary Thyroid Cancer

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 10, 2015, Pages 598-603

  Chung, J H ^a,b   Lee, Y C ^a,b   Eun, Y G ^a,b   Kim, S K ^a   Chon, S ^a   Oh, S J ^a   Rhee, S Y ^a   Hong, I K ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University ^*  (South Korea)

Author keywords

interleukin 18 polymorphism; single nucleotide; thyroid neoplasm interleukin 18 receptors

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; IL18R1 PROTEIN, HUMAN; INTERLEUKIN 18 PROTEIN, HUMAN; INTERLEUKIN 18 RECEPTOR ALPHA; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER RISK; CANCER SIZE; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CARCINOMA; AGED; CARCINOMA; CLINICAL TRIAL; GENETICS; MIDDLE AGED; THYROID TUMOR;

ADULT; AGED; CARCINOMA; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID NEOPLASMS;

EID: 84948187474     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0035-1559780     Document Type: Article

References (36)

1. Abubaker J., Jehan Z., Bavi P. et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab: 2008; 93 611 618
2. Sinnott B., Ron E., Schneider A. B. Exposing the thyroid to radiation: a review of its current extent, risks, and implications. Endocr Rev: 2010; 31 756 773
3. Fallah M., Pukkala E., Tryggvadottir L. et al. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries. J Med Genet: 2010; 50 373 382
4. Bozec A., Lassalle S., Hofman V. et al. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Current medicinal chemistry: 2010; 17 3449 3461
5. Coussens L. M., Werb Z. Inflammation and cancer. Nature: 2002; 420 860 867
6. Nakanishi K., Yoshimoto T., Tsutsui H. et al. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol: 2001; 19 423 474
7. Lee S. J., Cho Y. S., Cho M. C. et al. Both E6 and E7 oncoproteins of human papilloma virus 16 inhibit IL-18-induced INF-gamma production in human peripheral blood mononuclear and NK cells. J Immunol: 2001; 167 497 504
8. Dinarello C. A. Interleukin-18. Methods: 1999; 19 121 132
9. Osaki T., Peron J. M., Cai Q. et al. INF-gamma-inducing factor/IL-18 administration mediates IFN-gamma and IL-12-independent antitumor effects. J Immunol: 1998; 160 1742 1749
10. Sims J. E. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol: 2002; 14 117 122
11. Hoshino K., Tsutsui H., Kawai T. et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol: 1999; 162 5041 5044
12. Cheung H., Chen N. J., Cao Z. et al. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol: 2005; 174 5351 5357
13. Folwaczny M., Glas J., Török H. P. et al. Polymorphisms of the interleukin-18 gene in periodontitis patients. J Clin Periodontol: 2005; 32 530 534
14. Tone M., Thompson S. A., Tone Y. et al. Regulation of IL-18 (IFNgamma-inducing factor) gene expression. J Immunol: 2005; 159 6156 6163
15. Bresnihan B., Roux-Lombard P., Murphy E. et al. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis: 2002; 61 726 729
16. Amerio P., Frezzolini A., Abeni D. et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol: 2002; 20 535 538
17. Pages F., Berger A., Lebel-Binay S. et al. Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett: 2000; 75 9 14
18. Ushio S., Namba M., Okura T. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol: 1996; 156 4274 4279
19. Dinarello C. A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol: 1999; 103 11 24
20. Puren A. J., Fantuzzi G., Gu Y. et al. Interleukin-18 (IFN gamma-inducing factor) induces IL-8 and IL-1beta via TNF alpha production from non-CD14+ human blood mononuclear cells. Journal of Clinical Investigation: 1998; 101 711 719
21. Wei Y. S., Lan Y., Liu Y. G. et al. Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol: 2007; 17 1 7
22. Liu Y., Lin N., Huang L. et al. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol: 2007; 26 613 618
23. Nikiteas N., Yannopoulos A., Chatzitheofylaktou A. et al. Heterozygosity for interleukin-18 607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res: 2007; 27 3849 3853
24. Farhat K., Hassen E., Bouzgarrou N. et al. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine: 2008; 43 132 137
25. Vidal-Vanaclocha F., Mendoza L., Telleria N. et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev: 2006; 25 417 434
26. Takiyama Y., Miyokawa N., Tokusashi Y. et al. Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease. Thyroid: 2002; 12 935 943
27. Cunha L. L., Tincani A. J., Assumpção L. V. et al. Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo): 2011; 66 1203 1208
28. Coussens L. M., Werb Z. Inflammation and cancer. Nature: 2002; 420 860 867
29. Eun Y. G., Shin I. H., Lee Y. C. et al. Interleukin 22 polymorphisms and papillary thyroid cancer. Journal of endocrinological investigation: 2013; 36 584 587
30. Erdogan M., Karadeniz M., Ozbek M. et al. Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population. J Endocrinol Invest: 2008; 31 750 754
31. Eun Y. G., Shin I. H., Kim M. J. et al. Associations between promoter polymorphism-106A/G of interleukin-11 receptor alpha and papillary thyroid cancer in Korean population. Surgery: 2012; 151 323 329
32. Lee Y. C., Chung J. H., Kim S. K. et al. Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine: 2015; 71 283 288
33. Harness J. K., Thompson N. W., McLeod M. K. et al. Differentiated thyroid carcinoma in children and adolescents. World J Surg: 1992; 16 547 553
34. McHenry C. R., Rosen I. B., Walfish P. G. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg: 1991; 162 353 356
35. Sellers M., Beenken S., Blankenship A. et al. Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg: 1992; 164 578 581
36. Harwood J., Clark O. H., Dunphy J. E. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg: 1978; 136 107 110